In vitro detection of the MDR phenotype in rat myocardium: Use of PCR, [3H]daunomycin and MDR reversing agents

Anti-Cancer Drugs

Volumn 7, Issue 8, 1996, Pages 833-837

  Cayre, Anne ^b   Moins, Nicole ^a   Finat Duclos, Françoise ^a,b   Maublant, Jean ^a,b   Albuisson, Eliane ^c   Verrelle, Pierre ^a,b  

^a INSERM   (France)

^b CENTRE JEAN PERRIN   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

cardiac MDR phenotype; daunomycin; PCR; reversing agents

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; DAUNORUBICIN; GLYCOPROTEIN P; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; HEART MUSCLE CELL; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT;

EID: 0029772107     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199611000-00003     Document Type: Article

References (26)

1. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989; 58: 137-71.
2. Thiebaut F, Tsuoro T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug resistance gene product in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
3. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
4. Goldstein LJ, Galski H, Fojo AT, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
5. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990; 42: 155-99.
6. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993; 11: 1629-35.
7. Von Hoff DD, Layard M. Risk factors for development of daunorubicin cardiotoxicity. Cancer Treat Rep 1981; 65: 19-23.
8. Nielsen D, Maare C, Skovgaard T. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein. Influence of verapamil. Biochem Pharmacol 1994; 47: 2125-35.
9. Nielsen D, Maare C, Skovgaard T. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumour cells: correlation to expression of P-glycoprotein and efflux. Influence of verapamil. Biochem Pharmacol 1995; 50: 443-50.
10. Schinkel AH, Smit JJM, Van Tellingen O, et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994; 77: 491-502.
11. Bellamy WT, Peng YM, Odeleye A, et al. Cardiotoxicity in the SCID mouse following administration of doxorubicin and cyclosporin A. Anti-Cancer Drugs 1996; 6: 736-43.
12. Bisset D, Kerr DJ, Cassidy J, Meredith P, Traugott U, Kaye SB. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 1991; 64: 1168-71.
13. Harary I, Farley B. In vitro studies on single beating rat heart cells. Exp Cell Res 1963; 29 451-65.
14. Blondel B, Roijen I, Cheneval JP. Heart cells in culture: a simple method for increasing the proportion of myoblasts. Experientia 1971; 27: 356-8.
15. Deuchars KL, Duthie M, Ling V. Identification of distinct P-glycoprotein gene sequences in rat. Biochim Biophys Acta 1992; 1130: 157-65.
16. Dano K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973; 323: 466-83.
17. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985; 316: 820-3.
18. Thiebaut F, Tsuoro T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989; 37: 159-64.
19. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta 1980; 597: 1-14.
20. Goldman R, Facchinetti T, Bach D, Raz A, Shinitzky M. A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers. Biochim Biophys Acta 1978; 512: 254-69.
21. Pigram WJ, Fuller W, Hamilton DL. Stereochemistry of intercalation: interaction of daunomycin with DNA. Nature New Biol 1972; 235: 17-9.
22. Peterson C, Trouet A. Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts. Cancer Res 1978; 38: 4645-9.
23. Siegfried JM, Burke T, Tritton TR. Cellular transport of anthracyclines by passive diffusion. Implications for drug resistance. Biochem Pharmacol 1985; 34: 593-8.
24. Frezard F, Garnier-Suillerot A. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. Eur J Biochem 1991; 196: 483-91.
25. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 1979; 39: 2200-3.
26. Schwaller MA, Adenier A, Moreau F, Berlion M, Dunn T, Bizzari JP. Mechanism of uncoupling of S9788, a novel multidrug-resistance modulator, on rat liver mitochondria. Clin Exp Metastasis 1992; 10: 104.